Magnus Doverskog
Magnus Doverskog
Chief Executive Officer

Born 1967. CEO since 2012.

Education: Magnus has a master’s degree in organic chemistry and a Ph.D. in biotechnology from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm Business School, Stockholm University.

Experience: Magnus Doverskog has more than 20 years industry experience from discovery and development projects of both small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB. Post doctorial research at the European Molecular Biology Laboratory (EMBL) in Heidelberg where he obtained a Marie Curie individual Fellowship.

Other current assignments: –

Holdings in the Company: 176,991 warrants

Eva Arlander
Eva Arlander
Chief Development Officer

Born 1964. CDO since 2018.

Education: Eva has an M.Sc. in Pharmacy from Uppsala University and a Ph.D. in Clinical Pharmacology from the Karolinska Institute.

Experience: Eva Arlander has extensive experience from the pharmaceutical industry e.g., AstraZeneca, Medivir and Affibody with main focus on clinical development. She has led product development from phase 2 to commercialization in EU and US in the small pharma environment. Experience from leadership and executive roles in pharma companies and at the Swedish Medical Products Agency (MPA).

Other current assignments: Consultant at Synartro AB and Lipigon AB. CEO and consultant at SciGazer AB

Holdings in the company:

Hans Christopher Toll
Hans Christopher Toll
Chief Financial Officer

Born 1968. CFO since 2021.

Education: Hans Christopher has an M.Sc. in Economics from the Stockholm School of Economics.

Experience: Hans Christopher “HC” Toll has previous experience as CFO for companies within several industries since 2004, such as Portescap SA and KIN Group, and currently has consulting assignments for companies such as Cedergrenska AB, EcoBloom Sweden AB, Yabie AB and WeHype Global AB. Furthermore, he has experience from previous listings, and was during 2016 CFO for AIK Fotboll AB when it was listed on NGM, and assisted in the listings of FundedByMe and Cedergrenska AB on Nasdaq First North Growth Market.

Other current assignments: Board member of Livgrenadjärmässen Hotell- Fest- Konferens in Linköping AB, Hydra Consulting AB and HC Toll Control AB

Holdings in the company: –

Lars Öhman
Lars Öhman
Chief Business Officer

Born 1957. CBO since 2012.

Education: Lars holds an MBA from the Stockholm School of Economics.

Experience: Lars Öhman has more than 25 years wide-ranging research and business experience in senior positions at Karo Bio AB and Pharmacia. Proven track record in drug discovery and business development within the pharmaceutical industry. Responsible for in- and out-licensing of drug discovery and development projects to the pharmaceutical industry at Karo Bio during 2004-2012.

Other current assignments: Chairman of the board at Kubera Pharmaceuticals AB, Director of the Board and CBDO at Lipigon Pharmaceuticals AB, CEO at Kubator Therapeutics AB, Director of the Board and Principal at Cordator Life Science AB, CEO at Immunscape AB. Chairman of the board at Omnio AB. Chairman of the Board at Betulaceae Pharmaceuticals AB

Holdings in the company: 44,247 warrants.